Leerink Partnrs Predicts Sanofi’s Q1 Earnings (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) – Research analysts at Leerink Partnrs increased their Q1 2025 earnings per share estimates for shares of Sanofi in a research report issued to clients and investors on Sunday, March 30th. Leerink Partnrs analyst D. Risinger now expects that the company will post earnings of $0.88 per share for the quarter, up from their previous forecast of $0.85. The consensus estimate for Sanofi’s current full-year earnings is $4.36 per share. Leerink Partnrs also issued estimates for Sanofi’s Q2 2025 earnings at $0.93 EPS, Q3 2025 earnings at $1.64 EPS, Q4 2025 earnings at $0.94 EPS, FY2025 earnings at $4.39 EPS, FY2026 earnings at $5.00 EPS, FY2027 earnings at $5.03 EPS, FY2028 earnings at $5.49 EPS and FY2029 earnings at $6.02 EPS.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%.

SNY has been the subject of a number of other research reports. The Goldman Sachs Group began coverage on shares of Sanofi in a research note on Friday, March 21st. They issued a “neutral” rating and a $65.00 target price for the company. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Finally, StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Three analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $62.50.

Sanofi Price Performance

NASDAQ:SNY opened at $54.34 on Tuesday. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The firm has a market cap of $137.91 billion, a PE ratio of 21.82, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. Sanofi has a 12 month low of $45.22 and a 12 month high of $60.12. The company’s 50-day moving average price is $55.28 and its two-hundred day moving average price is $52.73.

Institutional Investors Weigh In On Sanofi

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Synergy Asset Management LLC acquired a new stake in Sanofi in the fourth quarter worth about $25,000. McClarren Financial Advisors Inc. boosted its stake in shares of Sanofi by 952.6% in the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares during the last quarter. Lee Danner & Bass Inc. acquired a new stake in shares of Sanofi during the 4th quarter worth approximately $31,000. Bessemer Group Inc. grew its position in shares of Sanofi by 59.8% during the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company’s stock worth $32,000 after buying an additional 242 shares during the period. Finally, Sunbelt Securities Inc. raised its stake in shares of Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after buying an additional 313 shares during the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.